Browsing: Access3

CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based biopharmaceutical company focused on harnessing its proprietary technologies to develop novel donor-derived cell-based immunotherapies for the treatment of various cancers, announces today that it signed a Memorandum of Understanding (MOU) with Hangzhou CNK Therapeutics Co., Ltd (CNK).

Since ChatGPT became a well-known name worldwide in early 2023, it has been trialled by millions and applied to a…

Combination of Ipilimumab and Nivolumab is one of the first line treatment recommended in patients with advanced renal-cell carcinoma with…

The American College of Cardiology had just released an expert consensus on the management of heart failure with preserved ejection…

New Data Shows Motor Gains with SRP-9001 Gene Therapy in DMD Duchenne Muscular Dystrophy (DMD) is a genetic disorder that…

Spinal muscular atrophy (SMA) is a rare genetic disease caused by a mutation in the survival motor neuron 1 (SMN1)…

Positive outcomes from two phase 3 trials suggest that Gepotidacin, an investigational oral antibiotic, holds promise as a groundbreaking, first-in-class…

How Advancements in Techniques and Technologies Empower Healthcare Professionals to Transform Patient Care The discipline of medicine has undergone a…

The FDA has granted 510(k) clearance to Advamedica’s Ax-Surgi surgical hemostat. It is the first and only chitosan-based hemostat cleared…

Spinal cord stimulation (SCS) device recently made news [1] when FDA expanded the indication for Abbott Laboratories’ SCS device to…